This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
midgardfinance.com
midgardfinance.com
did:plc:6elkozr74dmgtebnjmwcre7e
AstraZeneca enters the oral GLP-1 obesity race with SMD Elecoglipron. Phase 3 announced.
Top doses:
Elecoglipron 75 mg VISTA (P2): -11.8% wk 36
Orforglipron 36 mg ATTAIN-1 (P3): -12.4% wk 72
Semaglutide 50 mg OASIS-1 (P3): -15.1% wk 68
🇬🇧 $AZN 🇺🇸 $LLY 🇩🇰 $NOVO $NVO
#GLP1 #Obesity #Elecoglipron
2026-06-10T22:05:25.768Z